Eli Lilly and Stock Forecast for 2022 - 2025 - 2030

Updated on 05/28/2022

Stock Rating
5 / 10
Price Target
$321.00
Consensus
Outperform
Downside
-0.77%
Analysts
12
Stock Rating
16
Downside
-0.77%
Analysts
12
Price Target
$321.00

Based on the current earnings figures, this year's price targets for Eli Lilly and were recently set by twelve distinguished experts, with an average mark of $321.00. If it reached this goal, it would represent a potential downside of approximately -0.77% from the previous closing price in May, 2022. The high end is $369.00, and the low is $202.00. If you're looking for information on Eli Lilly and stock, consider checking out the forecasts for comparable firms such as NasdaqGS:AMGN.

$321.00

-0.77% Downside

Outperform
Outperform

Eli Lilly and Fair Value Forecast for 2022 - 2025 - 2030

Eli Lilly and's Fair Value has seen considerable growth in the last three years, going from $118.22 to $173.81 – a gain of 47.03% In the next year, analysts believe that Fair Value will reach an unimpressive $184.67 – an increase of 6.25% For the next nine years, the forecast is for Fair Value to grow by 148.04%

2022 Fair Value Forecast
$184.67
2023 Fair Value Forecast
$205.97
2024 Fair Value Forecast
$250.06
2025 Fair Value Forecast
$302.89
2026 Fair Value Forecast
$342.72
2027 Fair Value Forecast
$362.53
2028 Fair Value Forecast
$395.97
2029 Fair Value Forecast
$413.01
2030 Fair Value Forecast
$431.11
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
JNJ Stock Forecast Johnson & Johnson Outperform 12
$181.09 $187.12 2.71% 16
ROG Stock Forecast Roche Holding Outperform 0
CHF346.20 CHF384.23 12.94% 20
ABBV Stock Forecast AbbVie Outperform 9
$150.00 $164.23 11.83% 19
MRK Stock Forecast Merck Outperform 6
$93.08 $91.73 2.06% 19
TMO Stock Forecast Thermo Fisher Scientific Outperform 18
$572.35 $683.53 19.94% 15

Eli Lilly and Revenue Forecast for 2022 - 2025 - 2030

Eli Lilly and's Revenue has seen considerable growth in the last three years, going from $21.49B to $28.32B – a gain of 31.75% In the next year, analysts believe that Revenue will reach an unimpressive $28.51B – an increase of 0.66% For the next nine years, the forecast is for Revenue to grow by 69.31%

2022 Rev Forecast
$28.51B
2023 Rev Forecast
$30.45B
2024 Rev Forecast
$34.27B
2025 Rev Forecast
$38.90B
2026 Rev Forecast
$42.26B
2027 Rev Forecast
$43.57B
2028 Rev Forecast
$45.83B
2029 Rev Forecast
$47.19B
2030 Rev Forecast
$47.95B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
AZN Stock Forecast AstraZeneca PLC Outperform 18
£105.80 £136.08 37.87% 13
ABT Stock Forecast Abbott Laboratories Outperform 14
$116.69 $141.24 19.98% 19
NOVN Stock Forecast Novartis Outperform 0
CHF77.22 CHF103.75 19.24% 12

Eli Lilly and Dividend per Share Forecast for 2022 - 2025 - 2030

In three years, DPS for Eli Lilly and has grown by a whopping 51.11%, going from $2.25 to $3.40. In the coming year, analysts are expecting a moderate increase in DPS, predicting it will reach $3.78 – an increase of 11.18%. Over the next nine years, experts anticipate that DPS growth for Eli Lilly and will be 252.65%.

2022 DPS Forecast
$3.78
2023 DPS Forecast
$4.20
2024 DPS Forecast
$4.68
2025 DPS Forecast
$5.34
2026 DPS Forecast
$5.47
2027 DPS Forecast
$7.88
2028 DPS Forecast
$9.07
2029 DPS Forecast
$10.43
2030 DPS Forecast
$11.99
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
BMY Stock Forecast Bristol-Myers Squibb Outperform 2
$76.14 $76.69 5.07% 16
SAN Stock Forecast Sanofi Outperform 18
103.72€ 104.66€ 10.13% 20
AMGN Stock Forecast Amgen Hold 7
$255.26 $246.46 -2.06% 13

Eli Lilly and Free Cash Flow Forecast for 2022 - 2025 - 2030

Over the last three years, Eli Lilly and's Free Cash Flow has increased by 37.95%, going from $4.31B to $5.95B. In the next year, analysts are expecting a moderate increase in EPS, predicting it will reach $7.76B – an increase of 30.41%. The 2030 forecast is for Free Cash Flow to reach $15.12B or grow by 154.09%.

2022 FCF Forecast
$7.76B
2023 FCF Forecast
$8.00B
2024 FCF Forecast
$9.32B
2025 FCF Forecast
$10.94B
2026 FCF Forecast
$12.77B
2027 FCF Forecast
$14.28B
2028 FCF Forecast
$14.82B
2029 FCF Forecast
$15.14B
2030 FCF Forecast
$15.12B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
GSK Stock Forecast GlaxoSmithKline Outperform 16
£17.33 £16.08 3.87% 11
CSL Stock Forecast CSL Outperform 0
$266.28 $228.01 -14.01% 10
MRK Stock Forecast MERCK Kommanditgesellschaft au... Outperform 18
178.20€ 147.51€ 17.85% 15

Eli Lilly and Net Income Forecast for 2022 - 2025 - 2030

Eli Lilly and's Net Income has seen major growth over the last three years, jumping from $3.23B to $5.58B – an increase of 72.7%. In the next year, analysts predict that Net Income will reach a reasonable $7.88B – an increase of 41.25%. For the next nine years, the forecast is for Net Income to grow by 211.18%

2022 NI Forecast
$7.88B
2023 NI Forecast
$8.82B
2024 NI Forecast
$10.57B
2025 NI Forecast
$12.76B
2026 NI Forecast
$13.95B
2027 NI Forecast
$15.07B
2028 NI Forecast
$16.01B
2029 NI Forecast
$16.68B
2030 NI Forecast
$17.37B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
GILD Stock Forecast Gilead Sciences Outperform 11
$64.80 $75.96 6.48% 19
ZTS Stock Forecast Zoetis Outperform 18
$172.10 $235.45 45.26% 13
REGN Stock Forecast Regeneron Pharmaceuticals Outperform 2
$692.80 $696.64 1.04% 14

Eli Lilly and EBITDA Forecast for 2022 - 2025 - 2030

In the past three years, Eli Lilly and's EBITDA has seen a tremendous growth rate, increasing from $7.63B to $9.73B – an increase of 27.38%. For next year, the 12.00 analysts predict earnings per share of $10.44B, which would mean an increase of 7.3%. Over the next nine years, the pros' prediction is EBITDA of $20.45B, which would mean a 9-year growth forecast of 110.29%.

2022 EBITDA Forecast
$10.44B
2023 EBITDA Forecast
$11.82B
2024 EBITDA Forecast
$14.01B
2025 EBITDA Forecast
$17.51B
2026 EBITDA Forecast
$16.01B
2027 EBITDA Forecast
$17.17B
2028 EBITDA Forecast
$17.93B
2029 EBITDA Forecast
$18.95B
2030 EBITDA Forecast
$20.45B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
BDX Stock Forecast Becton, Dickinson and Outperform 17
$256.46 $270.20 11.13% 3
BAYN Stock Forecast Bayer Outperform 16
66.58€ 67.79€ 14.15% 14
4519 Stock Forecast Chugai Pharmaceutical Hold 18
¥3.79k ¥0.00 18.73% 0

Eli Lilly and EBIT Forecast for 2022 - 2025 - 2030

Eli Lilly and's EBIT has increased by 35.71% in the last three years, going from $6.03B to $8.18B. In the next year, analysts expect EBIT to reach a reasonable $9.13B – an increase of 11.7%. For the next nine years, the forecast is for EBIT to grow by 143.31%.

2022 EBIT Forecast
$9.13B
2023 EBIT Forecast
$10.24B
2024 EBIT Forecast
$12.44B
2025 EBIT Forecast
$15.21B
2026 EBIT Forecast
$16.48B
2027 EBIT Forecast
$18.00B
2028 EBIT Forecast
$19.05B
2029 EBIT Forecast
$19.75B
2030 EBIT Forecast
$19.90B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
4502 Stock Forecast Takeda Pharmaceutical Company Outperform 0
¥3.11k ¥0.00 28.53% 0
BAX Stock Forecast Baxter International Outperform 17
$76.16 $89.29 18.17% 3
BIIB Stock Forecast Biogen Outperform 11
$206.20 $287.21 10.33% 24

Eli Lilly and EPS Price Prediction Forecast for 2022 - 2025 - 2030

Eli Lilly and's EPS has seen considerable growth in the last three years, going from $5.55 to $8.16 – a gain of 47.03% In the next year, analysts believe that EPS will reach an unimpressive $8.67 – an increase of 6.25% For the next nine years, the forecast is for EPS to grow by 148.04%

2022 EPS Forecast
$8.67
2023 EPS Forecast
$9.67
2024 EPS Forecast
$11.74
2025 EPS Forecast
$14.22
2026 EPS Forecast
$16.09
2027 EPS Forecast
$17.02
2028 EPS Forecast
$18.59
2029 EPS Forecast
$19.39
2030 EPS Forecast
$20.24
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
4503 Stock Forecast Astellas Pharma Outperform 0
¥1.80k ¥0.00 33.33% 0
4507 Stock Forecast Shionogi & Outperform 0
¥7.81k ¥0.00 12.43% 0
FME Stock Forecast Fresenius Medical Care AG & Co... Hold 18
56.58€ 80.66€ 15.43% 11

© Copyright 2022 | Stock Forecast | All Rights Reserved